Eagle Health Investments LP Makes New $11.59 Million Investment in Tempus AI, Inc. $TEM

Eagle Health Investments LP bought a new stake in Tempus AI, Inc. (NASDAQ:TEM) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 256,269 shares of the company’s stock, valued at approximately $11,588,000. Tempus AI comprises 2.0% of Eagle Health Investments LP’s investment portfolio, making the stock its 19th biggest position.

A number of other institutional investors have also modified their holdings of TEM. GC Wealth Management RIA LLC purchased a new stake in shares of Tempus AI during the fourth quarter worth approximately $399,267,000. Voloridge Investment Management LLC grew its position in Tempus AI by 183.0% in the 3rd quarter. Voloridge Investment Management LLC now owns 1,607,083 shares of the company’s stock valued at $129,708,000 after buying an additional 1,039,176 shares during the last quarter. AQR Capital Management LLC purchased a new position in Tempus AI in the 2nd quarter valued at $54,020,000. Sumitomo Mitsui Trust Group Inc. increased its stake in Tempus AI by 23.4% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock valued at $195,636,000 after buying an additional 821,490 shares during the period. Finally, Amova Asset Management Americas Inc. increased its stake in Tempus AI by 23.4% in the 1st quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock valued at $195,549,000 after buying an additional 821,490 shares during the period. Institutional investors and hedge funds own 24.22% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently commented on TEM. Needham & Company LLC restated a “buy” rating and issued a $75.00 target price on shares of Tempus AI in a research note on Monday, July 20th. BTIG Research reiterated a “buy” rating and set a $80.00 price target on shares of Tempus AI in a research note on Monday, June 1st. Freedom Capital raised shares of Tempus AI to a “hold” rating in a report on Tuesday, June 30th. Lake Street Capital downgraded shares of Tempus AI to a “hold” rating in a research report on Monday, July 20th. Finally, Wall Street Zen raised Tempus AI from a “sell” rating to a “hold” rating in a report on Saturday. Nine analysts have rated the stock with a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $68.92.

Tempus AI Trading Up 0.5%

NASDAQ:TEM opened at $42.91 on Tuesday. Tempus AI, Inc. has a 1 year low of $41.73 and a 1 year high of $104.32. The company has a debt-to-equity ratio of 2.96, a quick ratio of 3.15 and a current ratio of 3.31. The stock has a fifty day moving average price of $51.63 and a two-hundred day moving average price of $53.30. The stock has a market capitalization of $7.71 billion, a price-to-earnings ratio of -24.95 and a beta of 3.46.

Tempus AI (NASDAQ:TEM) last issued its earnings results on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.08. Tempus AI had a negative net margin of 22.20% and a negative return on equity of 53.83%. The company had revenue of $348.12 million for the quarter, compared to analyst estimates of $345.44 million. During the same period in the previous year, the firm earned ($0.24) EPS. The business’s revenue was up 36.1% on a year-over-year basis. As a group, sell-side analysts anticipate that Tempus AI, Inc. will post -1.35 earnings per share for the current fiscal year.

Insider Transactions at Tempus AI

In other Tempus AI news, CEO Ryan Fukushima sold 33,284 shares of the stock in a transaction dated Wednesday, July 8th. The shares were sold at an average price of $57.39, for a total value of $1,910,168.76. Following the completion of the transaction, the chief executive officer directly owned 167,763 shares of the company’s stock, valued at approximately $9,627,918.57. This trade represents a 16.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Eric P. Lefkofsky sold 166,250 shares of the stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $57.48, for a total transaction of $9,556,050.00. Following the completion of the transaction, the chief executive officer directly owned 8,775,283 shares of the company’s stock, valued at approximately $504,403,266.84. This trade represents a 1.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 449,793 shares of company stock valued at $23,248,231. 24.26% of the stock is owned by company insiders.

Tempus AI Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.